The Chinese NDRC fines an healthcare company for price fixing for 4% of its sales revenue on cardiovascular, restorative therapy and diabetes medical device products in China (Medtronic)

On 7 December 2016, the NDRC announced that it had investigated and fined Medtronic for engaging in RPM in breach of the AML. The NDRC found that, since 2014, Medtronic had agreed with its distributors to limit the resale, tender, and minimum prices of its cardiovascular, restorative therapy, and

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • University of Melbourne
  • Hogan Lovells (Beijing)
  • China Competition Bulletin (Beijing)
  • University of Melbourne

Quotation

Allan Fels, Adrian Emch, Xiaoye Wang, Wendy Ng, The Chinese NDRC fines an healthcare company for price fixing for 4% of its sales revenue on cardiovascular, restorative therapy and diabetes medical device products in China (Medtronic), 7 December 2016, e-Competitions Bulletin December 2016, Art. N° 88643

Visites 47

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues